Physician profile
Michael R Raphael
NPI 1518170406
$20,657.41
in general payments reported to CMS, 2019-2025
40 companies · $1,230 in 2025
The $1,230 reported for 2025 was more than what a typical Gastroenterology (Internal Medicine) provider received nationally (typical 2025 total: $636).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $3,876 · 2020: $393 · 2021: $4,745 · 2022: $7,168 · 2023: $2,107 · 2024: $1,138 · 2025: $1,230.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $3,862 · Consulting Fee: $600 · Education: $13.76.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $3,861.79 |
| Consulting Fee | $600.00 |
| Education | $13.76 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| E.R. Squibb & Sons, L.L.C. | $7,800.00 | 2021-2022 | |
| Allergan, INC. | $1,866.39 | 2019-2020 | |
| Salix Pharmaceuticals, A Division of Bausch Health US, LLC | $1,788.33 | 2019-2025 | Xifaxan, Plenvu |
| Abbvie INC. | $1,760.57 | 2019-2025 | |
| Takeda Pharmaceuticals U.S.A., INC. | $1,506.09 | 2019-2025 | Entyvio, Eohilia, Gattex |
| Janssen Biotech, INC. | $1,500.43 | 2019-2025 | Stelara, Simponi Aria, Simponi |
| Celgene Corporation | $1,289.31 | 2021-2024 | Zeposia |
| Gilead Sciences, INC. | $388.53 | 2019-2025 | |
| Genzyme Corporation | $317.61 | 2022-2025 | |
| Pfizer INC. | $311.47 | 2019-2025 | |
| Ironwood Pharmaceuticals, INC | $269.73 | 2019-2025 | |
| Regeneron Healthcare Solutions, INC. | $207.42 | 2022-2024 | Dupixent |
| Ipsen Biopharmaceuticals, INC | $149.02 | 2025 | Iqirvo |
| Intercept Pharmaceuticals, INC. | $144.06 | 2019-2025 | |
| Qol Medical, LLC | $140.44 | 2019-2024 | Sucraid, Sucraid |
Show all 40 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Ucb, INC. | $120.24 | 2019 | |
| Celltrion USA INC. | $112.73 | 2024-2025 | Vegzelma |
| Ferring Pharmaceuticals INC. | $112.34 | 2019-2023 | Rebyota |
| Janssen Pharmaceuticals, INC | $107.07 | 2021 | |
| Ardelyx, INC. | $102.75 | 2022-2025 | Ibsrela |
| Madrigal Pharmaceuticals | $65.56 | 2025 | Rezdiffra |
| Braintree Laboratories, INC. | $62.27 | 2019-2023 | Suflave, Sutab |
| Amgen INC. | $59.79 | 2022-2023 | Avsola, Amjevita |
| Redhill Biopharma INC. | $55.13 | 2022-2023 | Talicia, Aemcolo, Movantik |
| Daiichi Sankyo INC. | $43.48 | 2019-2021 | |
| Lilly USA, LLC | $39.40 | 2024-2025 | Omvoh |
| Organon LLC | $38.96 | 2022-2025 | Hadlima, Renflexis |
| Nestle Healthcare Nutrition INC. | $38.26 | 2021-2023 | |
| Vivus LLC | $37.30 | 2021-2022 | |
| Welch Allyn | $34.46 | 2019 | |
| Alnylam Pharmaceuticals INC. | $29.84 | 2022 | |
| Concordia Pharmaceuticals INC. | $23.35 | 2019 | |
| Ethicon US, LLC | $20.43 | 2022 | |
| Astrazeneca Pharmaceuticals Lp | $17.87 | 2024 | Andexxa |
| Amag Pharmaceuticals, INC. | $17.83 | 2022 | |
| Shire North American Group INC | $16.74 | 2019 | |
| Merck Sharp & Dohme LLC | $16.37 | 2022 | |
| Alexion Pharmaceuticals, INC. | $16.37 | 2019 | |
| Evoke Pharma, INC. | $15.10 | 2022 | |
| Aimmune Therapeutics, INC. | $14.37 | 2024 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Michael Raphael listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.